Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study

BACKGROUND: The vascular endothelial growth factor receptor (VEGFR) pathway plays a pivotal role in solid malignancies and is probably involved in chemotherapy resistance. Pazopanib, inhibitor of, among other receptors, VEGFR1–3, has activity as single agent and is attractive to enhance anti-tumour...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Hamberg, P, Boers-Sonderen, M J, van der Graaf, W T A, de Bruijn, P, Suttle, A B, Eskens, F A L M, Verweij, J, van Herpen, C M L, Sleijfer, S
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2014
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3929878/
https://ncbi.nlm.nih.gov/pubmed/24366297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.798
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы